Aspire Biopharma Holdings (ASBP) Other Non-Current Liabilities (2023 - 2025)

Aspire Biopharma Holdings (ASBP) has reported Other Non-Current Liabilities for 3 consecutive years, with $40954.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Other Non-Current Liabilities fell 91.8% year-over-year to $40954.0 in Q4 2025; TTM through Dec 2025 was $40954.0, a 91.8% decrease from a year earlier, with the FY2025 full-year figure at $40954.0, down 91.8% from the prior year.
• Other Non-Current Liabilities was $40954.0 for Q4 2025 at Aspire Biopharma Holdings, down from $2.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $2.0 million in Q2 2025 and troughed at $40954.0 in Q4 2025.
• A 3-year average of $743605.1 and a median of $450000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 350.08% in 2025, down 91.8% in 2025.
• Over 3 years, Other Non-Current Liabilities stood at $155848.0 in 2023, then soared by 220.32% to $499213.0 in 2024, then slumped by 91.8% to $40954.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $40954.0 (Q4 2025), $2.0 million (Q2 2025), and $1.9 million (Q1 2025), per Business Quant data.